Success Metrics

Clinical Success Rate
74.2%

Based on 23 completed trials

Completion Rate
74%(23/31)
Active Trials
31(37%)
Results Posted
65%(15 trials)
Terminated
8(10%)

Phase Distribution

Ph phase_1
9
11%
Ph early_phase_1
1
1%
Ph phase_2
33
40%
Ph not_applicable
27
33%
Ph phase_3
2
2%

Phase Distribution

10

Early Stage

33

Mid Stage

2

Late Stage

Phase Distribution72 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
9(12.5%)
Phase 2Efficacy & side effects
33(45.8%)
Phase 3Large-scale testing
2(2.8%)
N/ANon-phased studies
27(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

63.9%

23 of 36 finished

Non-Completion Rate

36.1%

13 ended early

Currently Active

31

trials recruiting

Total Trials

83

all time

Status Distribution
Active(39)
Completed(23)
Terminated(13)
Other(8)

Detailed Status

Completed23
Recruiting17
Active, not recruiting14
Terminated8
Not yet recruiting7
unknown7

Development Timeline

Analytics

Development Status

Total Trials
83
Active
31
Success Rate
74.2%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.4%)
Phase 19 (12.5%)
Phase 233 (45.8%)
Phase 32 (2.8%)
N/A27 (37.5%)

Trials by Status

withdrawn56%
completed2328%
active_not_recruiting1417%
not_yet_recruiting78%
suspended11%
unknown78%
terminated810%
enrolling_by_invitation11%
recruiting1720%

Recent Activity

Clinical Trials (83)

Showing 20 of 83 trialsScroll for more
NCT03899987Phase 2

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Active Not Recruiting
NCT06651632Not Applicable

WATER IV Prostate Cancer

Active Not Recruiting
NCT03860987Phase 2

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Active Not Recruiting
NCT07439913

Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer

Enrolling By Invitation
NCT05710861Not Applicable

Cost-utility of Focal HIFU vs Prostatectomy

Recruiting
NCT04985565Not Applicable

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

Active Not Recruiting
NCT07516886

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Recruiting
NCT07490210Phase 2

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

Not Yet Recruiting
NCT03412396Phase 2

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Active Not Recruiting
NCT07455903Phase 2

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Not Yet Recruiting
NCT05726292Phase 2

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Recruiting
NCT01409200Phase 2

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Completed
NCT06631521Phase 1

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Recruiting
NCT05366842Phase 2

Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care

Terminated
NCT03456843Phase 2

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Active Not Recruiting
NCT07348367Not Applicable

A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.

Recruiting
NCT04981834Not Applicable

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer

Suspended
NCT02454543Not Applicable

Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases

Active Not Recruiting
NCT07162194Not Applicable

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

Recruiting
NCT02949284Phase 2

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Active Not Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
83